3,7-dimethyl-1-propargylxanthine and Autosomal Dominant Juvenile Parkinson Disease

3,7-dimethyl-1-propargylxanthine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alfinito, PD; Manzino, L; Rijhsinghani, S; Sonsalla, PK; Wang, SP; Zeevalk, GD	1
Beilstein, M; Castagnoli, K; Castagnoli, N; Chen, JF; Petzer, JP; Schwarzschild, MA; Sonsalla, PK; Staal, R; Xu, K; Xu, YH	1

Other Studies

2 other study(ies) available for 3,7-dimethyl-1-propargylxanthine and Autosomal Dominant Juvenile Parkinson Disease

Article	Year
Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Nov-26, Volume: 23, Issue:34 Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine; Drug Administration Routes; Drug Synergism; Electron Transport Complex II; gamma-Aminobutyric Acid; Huntington Disease; Male; Malonates; Mice; Mitochondria; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Theobromine; Tyrosine 3-Monooxygenase; Xanthines	2003
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2001, May-15, Volume: 21, Issue:10 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Catechols; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Immunity, Innate; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Purinergic P1; Theobromine; Triazoles; Xanthines	2001

Article

Year

Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.

The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Nov-26, Volume: 23, Issue:34

Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine; Drug Administration Routes; Drug Synergism; Electron Transport Complex II; gamma-Aminobutyric Acid; Huntington Disease; Male; Malonates; Mice; Mitochondria; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Theobromine; Tyrosine 3-Monooxygenase; Xanthines

2003

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

The Journal of neuroscience : the official journal of the Society for Neuroscience, 2001, May-15, Volume: 21, Issue:10

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Catechols; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Immunity, Innate; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Purinergic P1; Theobromine; Triazoles; Xanthines

2001